SCHEMBL4724997

SCHEMBL4724997

CCOC(=O)c1ccc(NC(=O)c2ccccc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 1.00
NPC1 O15118 5/20 1.00
RAB9A P51151 5/20 1.00
GAA P10253 3/20 1.00
MEN1 O00255 4/20 0.75
KMT2A Q03164 4/20 0.75
ALDH1A1 P00352 4/20 0.72
PTPN1 P18031 1/20 0.66
LMNA P02545 1/20 0.66
HTT P42858 1/20 0.66
MAPT P10636 3/20 0.64
NAMPT P43490 1/20 0.64
L3MBTL1 Q9Y468 2/20 0.64
KDM4E B2RXH2 1/20 0.63
ALOX15 P16050 1/20 0.63
TSHR P16473 1/20 0.61
TP53 P04637 1/20 0.61
CA12 O43570 1/20 0.61
CA9 Q16790 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10939388 0.95 SMN1; SMN2 (0.91) SMN1; SMN2NPC1RAB9AGAAMEN1
SCHEMBL10943445 0.94 RAB9A (0.88) SMN1; SMN2NPC1RAB9AGAAMEN1
SCHEMBL5879030 0.94 RAB9A (0.88) SMN1; SMN2NPC1RAB9AGAAMEN1
SCHEMBL9645441 0.93 SMN1; SMN2 (0.86) SMN1; SMN2NPC1RAB9AGAAMEN1
SCHEMBL14855964 0.89 SMN1; SMN2 (0.80) SMN1; SMN2NPC1RAB9AGAAMEN1
SCHEMBL31680576 0.89 RAB9A (0.81) SMN1; SMN2NPC1RAB9AGAAMEN1
SCHEMBL6707294 0.86 RAB9A (0.76) SMN1; SMN2NPC1RAB9AGAAMEN1
SCHEMBL4634907 0.86 MAPT (0.81) SMN1; SMN2NPC1RAB9AGAAMEN1
SCHEMBL9449917 0.86 RAB9A (0.76) SMN1; SMN2NPC1RAB9AGAAMEN1
SCHEMBL14096379 0.86 ALDH1A1 (0.78) SMN1; SMN2NPC1RAB9AGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115304507-A Synthesis method of N-substituted aryl formamide 兰州石化职业技术大学 2022-11-08 CN disclosed
US-20080242667-A1 Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases SMITHKLINE BEECHAM CORPORATION 2008-10-02 US disclosed
EP-1917258-A2 PYRIMIDINYL-PYRAZOLE INHIBITORS OF AURORA KINASES SmithKline Beecham Corporation (US) 2008-05-07 EP disclosed
WO-2007024843-A2 PYRIMIDINYL-PYRAZOLE INHIBITORS OF AURORA KINASES SMITHKLINE BEECHAM CORPORATION (US) 2007-03-01 WO disclosed
EP-0530579-B1 Condensed pyrimidine derivatives antitumor agents EISAI CO LTD (JP) 1998-11-11 EP disclosed
US-5688800-A ANTITUMOR AGENTS EISAI CO., LTD. (JP) 1997-11-18 US disclosed
US-5554615-A ANTITUMOR EISAI CO., LTD. (JP) 1996-09-10 US disclosed
EP-0542941-A1 N-PHENYL-BENZAMIDES PROVIDING PROTECTION FROM THE HARMFUL EFFECTS OF ULTRAVIOLET LIGHT. BAUDET PIERRE (CH) 1993-05-26 EP disclosed
CN-1070402-A The pyrimidine derivatives of condensation EISAI CO LTD (JP) 1993-03-31 CN disclosed
EP-0530579-A1 Condensed pyrimidine derivatives antitumor agents Eisai Co., Ltd. (JP) 1993-03-10 EP disclosed
WO-1992019208-A1 N-PHENYL-BENZAMIDES PROVIDING PROTECTION FROM THE HARMFUL EFFECTS OF ULTRAVIOLET LIGHT BAUDET PIERRE (CH) 1992-11-12 WO disclosed
EP-0346713-B1 BENZAMIDINES USEFUL AS ULTRAVIOLET LIGHT ABSORBERS L. GIVAUDAN & CIE Société Anonyme (CH) 1992-09-16 EP disclosed
US-5011628-A N,N'-diarylbenzamidines useful as ultraviolet light absorbers GIVAUDAN CORPORATION (US) 1991-04-30 US disclosed
EP-0346713-A1 Benzamidines useful as ultraviolet light absorbers L. GIVAUDAN & CIE Société Anonyme (CH) 1989-12-20 EP disclosed
US-4499167-A Photoconductive compositions comprising an organic photoconductor and an amide compound and electro-photographic light-sensitive materials using the compositions FUJI PHOTO FILM CO., LTD. (JP) 1985-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242667-A1 Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases AURKA, AURKC, PLK1 SMN1; SMN2 2084/4885NPC1 396/4885RAB9A 2549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.